The first results
The news was defined by Maurizio Di Mauro, the general manager of the Azienda Ospedali dei Colli, “something that widens the heart, perhaps like nothing else in this period“. Vincenzo Montesarchio, the infectious disease specialist of the Neapolitan health facility, who had started the treatment, together with colleague Paolo Ascierto of the Pascale Institute, on the result said: “The four patients performed very well, improving significantly in a few days“.
Studies on the drug
Among the health situations described by Dr. Montesarchio there was also a very young patient: “One is only 27 years old: he was in intensive care for severe pneumonia, even if he had no other serious conditions, if not asthma. Took the Tocilizumab on March 18 and now in assisted ventilation, he will soon be transferred to a normal Covid-19 hospital stay“According to the newspaper, the other three extubated were reported to have been treated on March 19 and are the first three people included in the experimentation Aifa on the current drug on 330 patients in Italy: three men aged 51, 55 and 56 years.
The situation in other countries
According to what reconstructed by the newspaper, meanwhile, in Germany, Holland, Greece and Australia, meanwhile, we continue with the experimentation of the tuberculosis vaccine. The start of the tests, announced by the magazine Science on his suito, he would test on a viral infection a vaccine born about a century ago to fight a bacterial infection. But to encourage the continuation of these tests would have been the positive effects that this injection has been shown to exert on the immune system, mobilizing the main defenses.
The tuberculosis vaccine
After a preliminary study conducted in Greece, at the university of Athens, the Dutch university of Utrecht would have already started to recruit a thousand healthy individuals in the health personnel working in eight hospitals and intends to start with the experimentation during the week. Other tests are scheduled in Australia, in the University of Melbourne, and in Germany, through the Max Planck Institute on the Biology of infections. The vaccine is called “Bacillus Calmette Guérin (Bcg)”, derived from the names of the French microbiologists Alber Calmette and Camille Guérin who got it first.
